Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicentre randomised double-blind study

David Chadwick*, J. Baldy-Moulinier, E. Ben-Manachem, R. Beran, A. Bes, L. D. Biermann, J. M. Bird, L. Boon, E. Byrne, E. P. Calandre, E. V. de Seijas, J. A. Tejerina, R. Canger, A. Saltarelli, N. E.F. Cartlidge, R. N. Corston, V. Cosi, C. Dellaportas, J. Duncan, W. Van PaesschenM. Dam, G. Danta, H. Gadot, A. N. Gale, D. Gisselbrecht, M. Gross, W. M. Guldenpfennig, J. Haan, S. J.L. Howell, G. S. Venables, J. Jankovic, R. Kälviäinen, P. Riekkinen, K. Kennedy, G. Kramer, P. H. Kritzinger, J. Manelis, R. Michelucci, C. A. Tassinari, M. Neufeld, B. Pederson, F. Pisani, A. Reches, B. Ried, E. A.C.M. Saunders, E. Somerville, L. Spechio, L. A. Neve, L. Tramacere, H. Stefan, A. Tartara, A. D. Van As, C. A. Van Donsellar, M. Weber, H. G. Wieser, G. Zaccara, G. T. Gomez

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

162 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicentre randomised double-blind study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science